Navigation Links
PrimeraDx Appoints David Jackson as VP of Business Development
Date:1/3/2012

MANSFIELD, Mass., Jan. 3, 2012 /PRNewswire/ -- PrimeraDx today announced that David Jackson has been appointed as the Vice President of Business Development.

"David has extensive capabilities in companion diagnostic partnerships, and his experience with DxS and Qiagen is well aligned with the company's strategy to be the platform of choice in the burgeoning companion diagnostics market," said Matt McManus, President and CEO, PrimeraDx.

"PrimeraDx has the most innovative qPCR based MDx platform in this space," commented Dr. Jackson.  "The strong growth in complex, molecular-based companion diagnostic assays makes this an exciting time to develop strategic alliances based around the high multiplex and multi-modal capabilities of the ICEPlex platform."

David Jackson has over 13 years' experience in the healthcare technology and investment industries.  Most recently David was employed at Qiagen as a member of the Companion Diagnostics Partnerships team in Global Business Development. Prior to Qiagen he held a similar VP role with DxS, which was acquired by Qiagen in 2009.  He has held leadership positions in business and corporate development; strategic marketing; commercialization; and intellectual property analysis. Dr. Jackson earned a doctorate in the medical sciences from the Boston University School of Medicine; is trained and experienced as a US Patent Agent and Securities Analyst.

About PrimeraDx

PrimeraDx is a molecular diagnostics company that has developed, and is commercializing, a novel, game-changing clinical platform which combines PCR with capillary electrophoresis.  The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative, answers to the clinic.  The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to collaborate with pharmaceutical companies to develop high-value companion and enabling diagnostic products.  Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.  PrimeraDx's technology represents the next generation of quantitative PCR.  The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysia Technology Development Corporation.  The Company's website is: www.primeradx.com or www.multiplexpcr.com.

CONTACT: Andrew Bond, +1-508-618-2752, abond@primeradx.com


'/>"/>
SOURCE PrimeraDx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PrimeraDx Appoints Leroy Hood to its Scientific Advisory Board
2. PrimeraDx Appoints David Heffelfinger as VP of Engineering and Systems Development
3. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
4. China Health Resource Appoints USA Acquisition Counsel
5. Winner Medical Appoints BDO China as Independent Auditor
6. Marken Appoints New Head of Global Quality Assurance
7. Delcath Appoints Gregory Gores, M.D. to Medical Advisory Board
8. Qforma Appoints Ian McGuinness as Vice President, Business Development
9. ZONARE Medical Systems Appoints Timothy S. Heher as Vice President of Finance
10. NeoStem Appoints a Biopharmaceutical Business Leader and a Cellular Therapy Expert to its Board of Directors
11. HealthpointCapital Acquires Blue Belt Technologies, Inc. and Appoints Eric B. Timko as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Research and Markets has announced the addition of ... their offering. The current ... environment for MedImmune to enter. The US ageing population creates ... drive considerable growth for effective anti-influenza medications. The introduction of ... but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented ... in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards honor the ... Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With this award, ...
Breaking Medicine News(10 mins):